Scrip: industry news and insights
Vera Pins Hopes On Per-Protocol Analysis To Revive Phase II IgAN Asset
31 Jan 2023
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial...
Navigating the issues presented by biosimilars is becoming more complicated. With new barriers facing biosimilar originator companies and threatening to derail development, knowing how to formulate and manage your own biosimilar action plan is critically important.
Explore the components essential for understanding how biosimilar originator companies are responding to threats to their profit margins with this webinar recording from Informa Pharma Intelligence.
Experts from Scrip, part of the Informa Pharma Intelligence suite of tools, used data from across Pharma Intelligence to present vital information about the issues facing the biosimilars market and what they might mean for the future.
Listen to the recording now, where Scrip experts will be:
The slides are available to download here
Scrip: industry news and insights
31 Jan 2023
The US firm is shifting its focus to IgAN after a promising new prespecified analysis of its Phase II trial...
Scrip: industry news and insights
31 Jan 2023
The Swedish biotech is stepping up its business development plans ahead of a mid-stage readout in the summer for ACD440...
Scrip: industry news and insights
31 Jan 2023
Comirnaty was the industry’s top-selling product through the first three quarters of 2022, as in 2021, but Paxlovid proved a...
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: